The middle of the week came with news from one of the most popular pharma companies right now due to its COVID-19 vaccine – Pfizer
Pfizer, the company that developed the first authorized COVID- 19 vaccine in the US, announced that it began in March an early-stage clinical trial of a new medicine for the disease. The new drug is a protease inhibitor and works by inhibiting an enzyme that the virus needs to replicate in human cells. These types of inhibitors are already being used in treating HIV and hepatitis C.
According to Pfizer CEO Albert Bourla, if everything goes smoothly and the FDA approves the drug, it will hit the shelves by the end of the year.
From the health experts’ perspective, the ingestible drug could be a game-changer because infected people could use it outside hospitals.
Besides the news drug, Pfizer is testing its vaccine in 6-months to 11-year-old children, after the company received from the FDA the authorization to expand its vaccine usage to adolescents aged between 12 – 15.
The market seemed to react positively to the news. At the moment of writing, Pfizer stock price is trading 0.57% higher.
Sources: cnbc.com, finance.yahoo.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com
JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.